A Phase 1 Study of TLN-372 in People With Advanced Solid Tumors

Full Title

An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-372 as a Single Agent and in Combination with Other Anti-Tumor Agents, in Patients with Advanced KRAS Mutant Solid Tumors

Purpose

Researchers want to find the best dose of TLN-372 in people with advanced solid tumors. The people in this study have cancer that has spread and has a mutation in the KRAS gene.

TLN-372 may help slow or stop the growth of your cancer by blocking the KRAS protein. 

Who Can Join

To join this study, there are a few conditions. You must:

• Have a solid tumor that has spread beyond its original location and has a KRAS mutation or KRAS amplification.
• Have recovered from the serious side effects of previous treatments before taking the study therapy.
• Be well enough to walk and take care of yourself. You must be able to do activities such as office work or light housework.
• Be age 18 or older.

Contact

For more information about this study or to see if you can join, please call 646-888-4226.